Drais In Third Deal With Astellas, Seeks To Expand Partnership Model
This article was originally published in The Pink Sheet Daily
Executive Summary
Astellas has returned for a third time to enlist the development services of Drais, out-licensing a nocturia candidate which Drais will house in a virtual development company, Tacurion. Drais’ challenge now is to expand its portfolio of single-asset companies and its roster of investors.
You may also be interested in...
Mesoblast’s Late-Stage Pipeline Could Be Game Changing: Are Investors Paying Attention?
Mesenchymal cell specialist Mesoblast came back from a near-death experience in 2016 when Teva returned a key asset. But recent success in a Phase III trial in acute GVHD has brought it some attention. Now it needs to repeat the achievement in advanced heart failure and find a partner for its burgeoning pipeline.
Ketamine May Shake Up The Treatment Of Major Depression
Pharmas have shied away from the challenging antidepressant market in recent years, but two late-stage ketamine-like candidates are leading the pack of novel agents in development.
The Disruptive Impact Of Retail Clinics
Retail health clinics are undergoing an intense period of partnering and business model change. Although the value proposition is rock solid, the real test will be whether clinics can offer complementary services to traditional primary care, and working with provider groups, help achieve the goal of population health management.